Clover Wolf Capital – Limited Buys 49,000 Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited acquired 49,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was purchased at an average price of $7.36 per share, for a total transaction of $360,640.00. Following the transaction, the insider now directly owns 2,601,311 shares of the company’s stock, valued at approximately $19,145,648.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Wednesday, June 10th, Clover Wolf Capital – Limited acquired 25,000 shares of Pluristem Therapeutics stock. The stock was purchased at an average price of $6.91 per share, for a total transaction of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited bought 178,717 shares of Pluristem Therapeutics stock. The shares were bought at an average cost of $7.36 per share, for a total transaction of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited bought 7,610 shares of Pluristem Therapeutics stock. The shares were bought at an average cost of $7.86 per share, for a total transaction of $59,814.60.
  • On Tuesday, June 2nd, Clover Wolf Capital – Limited acquired 117,489 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $7.57 per share, for a total transaction of $889,391.73.
  • On Sunday, May 31st, Clover Wolf Capital – Limited acquired 1,797 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $7.95 per share, for a total transaction of $14,286.15.
  • On Wednesday, May 27th, Clover Wolf Capital – Limited acquired 90,000 shares of Pluristem Therapeutics stock. The shares were acquired at an average cost of $8.14 per share, for a total transaction of $732,600.00.

Shares of PSTI stock opened at $8.84 on Wednesday. Pluristem Therapeutics Inc. has a 12 month low of $2.82 and a 12 month high of $13.29. The stock has a market cap of $219.17 million, a P/E ratio of -2.68 and a beta of 2.60. The company has a current ratio of 2.47, a quick ratio of 2.47 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $8.28 and a two-hundred day simple moving average of $5.75.

Several research analysts have recently issued reports on the stock. Maxim Group reiterated a “buy” rating and issued a $12.00 target price on shares of Pluristem Therapeutics in a research note on Friday, May 15th. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Jefferies Financial Group assumed coverage on shares of Pluristem Therapeutics in a research note on Friday, June 19th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.50 target price on shares of Pluristem Therapeutics in a research note on Thursday, May 14th. Finally, Dawson James reissued a “buy” rating on shares of Pluristem Therapeutics in a report on Wednesday, April 15th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Pluristem Therapeutics has a consensus rating of “Buy” and a consensus price target of $12.20.

Hedge funds have recently made changes to their positions in the business. Levin Capital Strategies L.P. purchased a new stake in Pluristem Therapeutics during the first quarter valued at approximately $37,000. ETF Managers Group LLC increased its holdings in Pluristem Therapeutics by 9.8% during the first quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 5,764 shares during the last quarter. Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 303.9% during the fourth quarter. Jane Street Group LLC now owns 67,349 shares of the biotechnology company’s stock valued at $265,000 after buying an additional 50,674 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Pluristem Therapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock worth $1,077,000 after purchasing an additional 87,188 shares in the last quarter. 7.82% of the stock is owned by institutional investors and hedge funds.

About Pluristem Therapeutics

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.